PRPS1 S103I

CI-VAR-00003971Explore in graph →CIViC 2925

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma2
PRPS1 S103I	(prognostic)	Prognostic	C	Supports Poor Outcome	3	submitted	EID7884 PRPS1 exons were sequenced in the diagnosis and relapse samples of 358 B-Cell Childhood Acute Lymphoblastic Leukemia relapse patients (138 Chinese and 220 German). PRPS1 S103I was detected only at rel… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic
PRPS1 S103I	Mercaptopurine + ThioguanineSubstitutes	Predictive	D	Supports Resistance	4	accepted	EID7905 Lentiviral-mediated overexpression of PRPS1 S103I in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apopto… (full text at CIViC) PMID 25962120 · Li et al., 2015 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.